Neuralstem, Inc. (NASDAQ:CUR) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $1.13 and last traded at $1.13, with a volume of 551,074 shares traded. The stock had previously closed at $1.26.

Separately, ValuEngine downgraded Neuralstem from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th.

The stock has a 50 day moving average price of $4.95 and a 200 day moving average price of $4.57. The firm’s market cap is $13.68 million.

In other Neuralstem news, CEO Richard J. Daly bought 7,500 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The shares were purchased at an average cost of $4.00 per share, for a total transaction of $30,000.00. Following the transaction, the chief executive officer now owns 23,312 shares of the company’s stock, valued at $93,248. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 15.43% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Neuralstem stock. Blair William & Co. IL boosted its stake in shares of Neuralstem, Inc. (NASDAQ:CUR) by 171.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,343 shares of the company’s stock after buying an additional 55,115 shares during the period. Blair William & Co. IL owned approximately 0.73% of Neuralstem worth $506,000 as of its most recent filing with the SEC. Institutional investors own 12.46% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Neuralstem, Inc. (NASDAQ:CUR) Hits New 12-Month Low at $1.13” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.